Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Trever G. Bivona, M.D., Ph.D.
Trever G. Bivona, M.D., Ph.D.

Trever G. Bivona, M.D., Ph.D.

Assistant Professor in Residence
Division of Hematology/Oncology
Department of Medicine

Contact Information

University of California, San Francisco
Mission Bay/Genentech Hall
600 16th Street, Room: N212D
San Francisco, CA 94158-2140
UCSF intercampus mail, please use mail code: 2140 
TBivona@medicine.ucsf.edu
Phone: 415-476-9907 / Lab Fax: 415-514-0169 / Clinic Fax #: 415-514-6676

Open Popup
  • Vanderbilt University, B.S., 1998, Molecular Biology
  • New York University, School of Medicine, Ph.D., 2004, Cell and Mol. Biology
  • New York University, School of Medicine, M.D., 2005, Medicine
  • Brigham and Women's Hospital/Harvard, 2005-2007, Internal Medicine
  • Memorial Sloan-Kettering Cancer Center, 2007-2011, Medical Oncology
  • Research Fellow, Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 2008-2011
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology
  • Department of Medicine, Division of Hematology/Oncology
  • Thoracic Oncology Program
  • Member, UCSF Helen Diller Family Comprehensive Cancer Center
  • Member, UCSF Biomedical Sciences Graduate Program (BMS)
  • Member, California Institute for Quantitative Biosciences (QB3)
  • Bronchioloalveolar Carcinoma (BAC)
  • Chest Wall Tumors
  • Lung Carcinoid Tumors
  • Lung Metastases
  • Malignant Mesothelioma
  • Mediastinal Tumors
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Target Therapies in Lung Cancer
  • Thymoma & Thymic Carcinoma
  • Activating mutations in EGFR
  • Lung cancer
  • Mechanisms of Secondary Resistance
  • Molecular pathogenesis of human cancers
  • Molecularly-targeted cancer therapies
  • Next-generation functional genomics
  • Novel, rational therapeutic strategies

Trever G. Bivona, M.D., Ph.D. is a thoracic medical oncologist. His overarching goal is to develop paradigm-shifting treatment strategies that target the aberrant signal transduction pathways fueling tumor growth. He is Director of the Bivona Lab, a bench-to-bedside research enterprise investigating the molecular pathogenesis of human cancers, primarily lung cancer. In pursuit of that goal, the Bivona Lab uses interdisciplinary approaches and next-generation functional genomics methodologies, highly relevant cell line and tumor model systems, and human tumor specimens and clinical outcomes data. These help to define and elucidate the molecular events driving human lung cancer growth. 

Dr. Bivona received his M.D. and Ph.D. from the joint Medical Scientist Training Program at NYU School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital followed by advanced training at Memorial Sloan-Kettering Cancer Center as a medical oncology fellow, and research fellow in the Laboratory of Charles Sawyers, Human Oncology and Pathogenesis Program.

I am a laboratory-based physician-scientist and an academic medical oncologist with a Ph.D. in cell and molecular biology. Clinical experiences inspire my laboratory investigations and provide opportunities to translate scientific discoveries aimed at improving the personalized treatment of cancer patients.  The goal of my research program is to define the molecular pathogenesis of human cancers through both basic and translational studies with a particular focus on lung cancer, the leading cause of cancer mortality in the United States.

Our aim is to discover tumor-cell specific vulnerabilities that can be therapeutically exploited as novel treatment strategies to improve the survival of patients with lung, and potentially, other cancers.  To accomplish our goals, we have a developed an integrated approach to define the molecular mechanisms by which oncogenes drive the growth of human lung cancers and by which tumors evade oncogene-targeted treatments.

Our approach leverages state-of-the-art functional genomics RNA interference screening methodologies, highly relevant preclinical models of lung cancer that accurately represent human lung cancer, and prospectively acquired human lung cancer specimens and clinical data.  Using this approach we recently identified several novel mechanisms of resistance to EGFR (epidermal growth factor receptor) inhibitors in lung cancers with activating (oncogenic) mutations in EGFR. Our work has defined new rational companion therapeutic targets that when inhibited may enhance responses to EGFR inhibitors in lung cancer patients

The studies proposed in this project build upon our prior research because they will allow us to further define molecular determinants of oncogene dependence in human lung cancers. Moreover, we are uniquely positioned to translate our findings into lung cancer patients through validation of our findings in human lung cancer specimens and, subsequently, hypothesis-driven clinical trials in lung cancer patients.

Most recent publications from a total of 96
  1. Fan Q, An Z, Wong RA, Luo X, Lu E, Baldwin A, Mayekar MK, Haderk F, Shokat KM, Bivona TG, Weiss WA. Betacellulin drives therapy-resistance in glioblastoma. Neuro Oncol. 2019 Nov 03. View in PubMed
  2. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2019 Sep 23. View in PubMed
  3. Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R. BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers (Basel). 2019 Sep 17; 11(9). View in PubMed
  4. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 Aug 27; 28(9):2317-2330.e8. View in PubMed
  5. Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019 Aug 16; 11(8). View in PubMed
  6. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019 07 22; 129(8):3401-3406. View in PubMed
  7. McCoach CE, Bivona TG. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov. 2019 May; 9(5):587-604. View in PubMed
  8. Bivona TG. Dampening oncogenic RAS signaling. Science. 2019 03 22; 363(6433):1280-1281. View in PubMed
  9. Chatterjee N, Bivona TG. Polytherapy and Targeted Cancer Drug Resistance. Trends Cancer. 2019 Mar; 5(3):170-182. View in PubMed
  10. Halliday PR, Blakely CM, Bivona TG. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Curr Oncol Rep. 2019 Feb 26; 21(3):21. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Trever G. Bivona, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

 

Site Directory
    X